Delivery Order SPE2DB24D2215-SPE2DB25FGSHD

Award Date 1/17/25
Potential Completion Date 1/21/25
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a leading pharmaceutical distributor, for the supply of ELIQUIS 5 MG TABLET 60S. The order, valued at $13,071.54, is a firm fixed-price contract with a completion date of July 26, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,302.38 firm-fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of November 20, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Eliquis 5 mg tablets. The contract award has a firm fixed price of $35,732.60 and a period of performance through January 16, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ELIQUIS 5 MG TABLET 60S. The $7,064.67 contract has a completion date of November 15, 2024 and was awarded on November 14, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of ELIQUIS 5 MG TABLET 60S. The fixed-price delivery order, valued at $7,164.38, has an ultimate completion date of August 30, 2022. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ELIQUIS 5 MG TABLET 60S. The contract has a ceiling value of $50,731.42 and is a Firm Fixed Price contract type with a completion date of January 6, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,964.85 firm fixed price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a prescription medication. The contract has an ultimate completion date of December 9, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $33,999.21 Firm Fixed Price delivery order is for ELIQUIS 5 MG TABLET 60S, a specialty pharmaceutical product. The contract has an ultimate completion date of December 20, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $7,448.42, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, and has an ultimate completion date of October 25, 2024. The contract is a Delivery Order, with a Firm Fixed Price pricing type. This award is not designated as a Set-Aside contract. AmerisourceBergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $32,722.72 firm fixed price delivery order is for the supply of 4566987549 ELIQUIS 5 MG TABLET 60S, a medication used for various medical conditions. The contract has an ultimate completion date of January 22, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB24D2215
    Indefinite Delivery Contract
  • SPE2DB24D2215-SPE2DB25FGSHD
    Delivery Order

This is a Delivery Order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ELIQUIS 5 MG TABLET 60S. The contract has a firm fixed price of $3,412.65 and an ultimate completion date of January 21, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 4/21/25, 3:48 AM